Financing for Cannabis-Adjacent and Regulated Industries: What Actually Gets Bank-Financed

A packaging company sells child-resistant containers to licensed cannabis operators in twelve states. Revenue is up 40 percent year over year. Margins are healthy. Receivables are aging well. The company applies for a bank line of credit and is told, politely, that the risk committee cannot get comfortable. The same happens at the second bank. And the third.

The company is not in the cannabis business. It is in the packaging business. But it services cannabis operators, and that is enough to knock it out of most bank credit boxes. This is the cannabis-adjacent problem — real, profitable, growing companies with legitimate collateral and audited financials that cannot get traditional bank financing because their customer list touches a federally-illegal industry.

This piece is for the CFO or owner of a cannabis-adjacent business — packaging, equipment, technology, security, real estate, testing, consulting, professional services — trying to figure out where the financing actually is. Not lender-side theory. What actually gets funded, and by whom.

Why bank financing is hard even when you never touch the plant

Federal law still treats cannabis as a Schedule I controlled substance. Federally-chartered banks and most state-chartered banks that hold FDIC insurance treat any material customer revenue derived from cannabis as a regulatory risk. The regulator concern is not that the packaging company itself is illegal. It is:

• Anti-money-laundering compliance. Under FinCEN guidance, financial institutions serving marijuana-related businesses (MRBs) must file Suspicious Activity Reports (SARs) on every transaction. Most banks decline to build the compliance infrastructure. If the packaging company deposits checks from a licensed dispensary, the bank has to decide whether to treat those deposits under MRB protocols.
• Reputation risk. Bank boards and enterprise risk committees have varying appetites for cannabis-adjacent exposure regardless of the FinCEN mechanics. Some banks will not lend to a company where more than 10 percent of revenue comes from cannabis operators. Some will not go past zero.
• Collateral realization. If the bank has to enforce against inventory sitting in a cannabis operator's warehouse — the packaging is finished goods until delivered and paid for — repossessing it involves entering a licensed facility. Not every bank's workout desk wants that phone call.
• Correspondent bank cascade. Even where the direct bank is willing, correspondent banks that clear and process transactions may not be. This is the invisible layer of the problem — the lending bank is willing, its correspondent bank objects, and the deal cannot close.

None of these apply to the packaging company itself. All of them shape what financing is actually available.

The three financing markets for cannabis-adjacent businesses

Financing for cannabis-adjacent businesses lives in three distinct markets. Which one fits depends on how much of revenue comes from cannabis operators, how the business is structured, and how much cost the borrower is willing to accept.

1. Cannabis-comfortable banks and community lenders

A growing but still-small number of state-chartered banks and credit unions have built the compliance infrastructure to serve cannabis-adjacent (and in some cases direct-plant-touching) businesses. They file the required SARs, run enhanced due diligence on borrowers, and price for the compliance overhead. These lenders exist in states with mature cannabis markets — California, Colorado, Washington, Oregon, Massachusetts, Michigan, Illinois, New Jersey, New York — and increasingly in states with newer programs.

The lenders in this category are small. Loan sizes typically run $500,000 to $10 million. Pricing sits above traditional bank pricing but well below alternative lender pricing. For a cannabis-adjacent packaging or equipment company with $5M-$25M in revenue, this is often the natural home if any of it exists in the relevant states.

The catch: geography and capacity. If the bank is in Colorado and the borrower operates nationally, the bank may or may not lend across state lines. If the bank is small and has capital allocated to cannabis at 10 percent of its lending portfolio, it may be closed to new relationships for a period. Availability is real but not universal.

2. Specialty ABL and private credit lenders

Above the community-bank threshold sits a group of specialty asset-based lenders and private credit funds that have built cannabis-adjacent (and often direct) practices. These lenders operate outside the FDIC-insured deposit system for the most part — they are not banks, they are not taking retail deposits, they are not subject to the same correspondent-bank cascade. They can lend against receivables and inventory of a cannabis-adjacent business without the same compliance friction.

Loan sizes here typically start at $5M and can run $50M or higher. The advance rates on eligible A/R and inventory are broadly comparable to a traditional ABL — the collateral analysis is the same collateral analysis regardless of industry — but the pricing is higher, reflecting the smaller lender pool and the compliance and reputation overhead. All-in cost typically runs 200-400 basis points above where the same collateral pool would price in a traditional bank ABL.

The trade-off is available capital and covenant flexibility. Where a bank cannot lend at all, a specialty lender can size to a real facility off real collateral. Where a bank would impose availability blocks and cash dominion at the first sign of stress, a specialty lender is often more accustomed to the industry cadence and does not tighten as reflexively.

3. Non-cannabis carve-out structures

The third path is structural: separate the cannabis revenue into a subsidiary and finance only the non-cannabis part of the business at a traditional bank. This works when the business has a meaningful non-cannabis revenue stream — the packaging company that sells to nutraceuticals, cosmetics, and food-and-beverage as well as cannabis; the security company that services cannabis dispensaries and non-cannabis retail; the testing lab that runs both cannabis and pharmaceutical assays.

The mechanics are straightforward but not costless: the cannabis-facing revenue is booked in a separate legal entity, that entity is excluded from the credit group (an "Unrestricted Subsidiary" or excluded from the guaranty package — see the general guaranty structure walkthrough), and the borrowing base is built off the non-cannabis entity's receivables and inventory only. The bank's credit committee is comfortable because their exposure sits entirely outside the cannabis chain.

This structure works when the numbers work. If the non-cannabis revenue supports a facility that meets the business's needs, it can be a clean solution. If the non-cannabis piece is too small to size to what the business actually needs, the carve-out is decorative and the business is back in markets 1 or 2.

What lenders actually diligence differently

A cannabis-adjacent underwriting looks broadly like any ABL underwriting — collateral, cash flow, management, financials — but with several specific overlays.

Customer concentration measured differently

Traditional customer concentration analysis looks at concentration by individual customer. Cannabis-adjacent underwriting also looks at concentration by industry — what percentage of revenue derives from cannabis operators as a category. That percentage matters because it determines which lending market the borrower fits into (bank-financeable at 10 percent, cannabis-comfortable bank at 30 percent, specialty ABL at 60 percent and up).

Collateral realization pathway

The lender wants to understand what a wind-down looks like. Receivables from licensed operators — how are they collected in a normal course, are payments in cash or ACH or wire, is there a factoring or A/R purchase relationship in the chain. Inventory sitting at customer locations — how is it accounted for, when does title transfer, is there consigned inventory sitting on cannabis licensee premises (this is an eligibility red flag). The realistic answer to "how do you liquidate this collateral" is a real underwriting question.

Regulatory trajectory

Every cannabis-adjacent lender is watching the regulatory trajectory — SAFE Banking Act status at the federal level, state licensing rules where the borrower operates, DEA rescheduling proposals, any state-level enforcement events that could change customer solvency overnight. The borrower's own regulatory-tracking discipline is part of the underwriting story.

Concentration by state

A packaging company with 60 percent of cannabis revenue in one state is a different risk than one with cannabis revenue diversified across ten states. If that one state changes its regulatory regime, the concentrated borrower has an existential exposure. Diversification across states is a real risk mitigant.

The customer license file

Lenders will typically ask for evidence that customers are licensed operators in good standing — copies of state licenses, verification of good-standing status, sometimes ongoing quarterly attestation. This is not about the borrower's legality; it is about the counterparty risk that a customer license could be suspended.

What borrowers should have ready before approaching the market

• Revenue by segment. Split cannabis-facing revenue from non-cannabis revenue by customer, by product line, and by state. Show the trend.
• A/R aging by customer type. Separately show aging for cannabis-adjacent customers vs. non-cannabis. Payment behavior often differs; showing you know it differs is credibility.
• Customer license documentation. A file of current license copies for the top customers by revenue. This will be requested and should be in shape before it is asked for.
• Regulatory trajectory memo. One page on what regulatory changes matter to the business and how management tracks them. Not a lobbying document; a risk-management document.
• Entity structure. Whether the current entity structure allows a carve-out subsidiary strategy, and what the tax and operational consequences of restructuring would be.
• A collateral summary that would work in a wind-down. Where is inventory, who has title when, how would receivables be collected if collection support were needed.

Where DCE fits

Don Clarke — SFNet Hall of Fame 2021, Lifetime Achievement Award, author of "Asset Based Lending Disciplines" (the first ABL textbook), and trainer of more than 5,000 professionals at GE Capital, JP Morgan Chase, Lloyds, and Barclays — spent his career in traditional bank ABL before establishing DCE as an independent advisor to borrowers. The cannabis-adjacent market has developed largely outside the traditional bank ABL world, but the underwriting is still recognizably ABL — collateral analysis, cash flow, management assessment — with a regulatory overlay. DCE advises cannabis-adjacent borrowers on which lending market fits their profile, whether a non-cannabis carve-out subsidiary is worth the operational complexity, and how to prepare the collateral, customer, and regulatory files for a market where compliance overhead is a real underwriting item. We introduce borrowers to lenders — including a smaller pool of cannabis-comfortable community banks and specialty ABL lenders — whose credit box actually fits their business.

ABLC (ablc.net) is DCE's sister firm serving lenders with due diligence, field examination, and training services — including for lenders operating in cannabis-adjacent and regulated-industry portfolios.

Educational only; not legal, tax, or accounting advice. Cannabis regulation is federal and state and changes frequently. Borrowers should consult qualified counsel and accountants on structure, licensing, tax, and any regulatory questions specific to their business and jurisdictions.